데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
1792993-84-0COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.ClHJVGDXBEMFHGKI-BQAIUKQQSA-NSee also: Daridorexant (has active moiety).
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
H411 (50%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]
P273, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
개요Daridorexant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for insomnia.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
1792993-84-0CHEMBL4650216